908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer

BOSTON–(BUSINESS WIRE)–908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL™ cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams.

“We are pleased that GSK has once again chosen our REBEL desktop device as part of its process development efforts to bring promising therapeutics to market,” said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. “The REBEL analyzer enables our biopharma customers to make critical decisions on optimizing cell cultures in minutes, and its small desktop footprint fits alongside bioreactors in process development labs.”

908 Devices notes there are now 15 customers owning multiple REBEL devices, more than double from one year ago. In addition, all 20 of the top 20 pharmaceutical companies are now using the company’s desktop devices, which include REBEL and ZipChip®, in their development process.

About the REBEL analyzer

REBEL is the first miniature CE-MS-based analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line. Key benefits include:

• Samples can be run in minutes, eliminating core lab wait time of days and even weeks.
• Quantitate over 30 components in cell culture media, including amino acids, dipeptides, water-soluble vitamins and amines.
• Easy to use with an intuitive user interface and touchscreen, and the REBEL’s small footprint permits flexibility in the lab layout.

For more information, visit www.908devices.com.

About 908 Devices

908 Devices Inc. (NASDAQ: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC’s website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

Contacts

Media

Katie Johnston

PAN Communications for 908 Devices

[email protected]

Investor

Carrie Mendivil

[email protected]